Li Shan, Wang Lingfei, Hu Yongzhou, Sheng Rong
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Curr Top Med Chem. 2015;15(8):720-44. doi: 10.2174/1568026615666150302105343.
Autophagy is an important basic metabolic mechanism by engulfing and degrading the unnecessary or dysfunctional cellular components within double-membered autolysosomes to maintain cellular homeostasis. Autophagy has sparkled great interest for its complicated functions in different stages of cancer, and is regarded as a potential target for anticancer therapy. As a suppressor pathway, autophagy prevents tumor initiation and as a survival pathway, autophagy contributes to tumor growth and progression by attenuating cellular metabolic stress and resisting therapeutic agents-induced cell death. Many autophagy regulators have been identified as potential cancer therapeutic agents and some cytotoxic anticancer drugs also induce autophagy. Combination regimen of autophagy regulators with other anticancer agent exhibits desirable efficacy and several protocols are underway in clinical trials. This review delineates the possible role of autophagy in anticancer therapy, and discusses reported potent autophagy regulators in cancer treatment.
自噬是一种重要的基本代谢机制,通过在双膜自噬溶酶体内吞噬和降解不必要或功能失调的细胞成分来维持细胞稳态。自噬因其在癌症不同阶段的复杂功能而引发了极大的兴趣,并被视为抗癌治疗的潜在靶点。作为一种抑制途径,自噬可预防肿瘤发生;而作为一种存活途径,自噬通过减轻细胞代谢应激和抵抗治疗药物诱导的细胞死亡来促进肿瘤生长和进展。许多自噬调节因子已被鉴定为潜在的癌症治疗药物,一些细胞毒性抗癌药物也可诱导自噬。自噬调节因子与其他抗癌药物的联合方案显示出理想的疗效,并且有几种方案正在进行临床试验。本综述阐述了自噬在抗癌治疗中的可能作用,并讨论了报道的在癌症治疗中有潜力的自噬调节因子。